Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuelle Samalin

Showing results (31-40 of 68) with videos related to

Pageof 7
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 28, 2017
Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)Christophe Locher, Blaise Batumona, Pauline Afchain, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 17, 2024
Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patientsEmmanuelle Samalin, Thibault Mazard, Eric Assenat, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 7, 2013
Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohortSimon Pernot, Emmanuel Mitry, Emmanuelle Samalin, et al.
Advances in Therapy|April 14, 2022
Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE StudyDenis Smith, Côme Lepage, Eric Vicaut, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 14, 2016
Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective studyFlorence Mary, Aziz Zaanan, Valérie Boige, et al.
International Journal of Cancer|January 6, 2021
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1)Eric Assenat, Laurent Mineur, Caroline Mollevi, et al.
Oncotarget|April 29, 2015
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trialEric Assenat, David Azria, Caroline Mollevi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 7, 2019
Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failureMaïlys de Meric de Bellefon, Claire Lemanski, Florence Castan, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2017
Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effectsSimon Pernot, Cecile Badoual, Magali Terme, et al.
Targeted Oncology|April 13, 2021
The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib ProgramThomas Aparicio, Nathalie Cozic, Christelle de la Fouchardière, et al.
Pageof 7

Showing results (31-40 of 68) with videos related to

Sort By:
Pageof 7
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 28, 2017
Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)Christophe Locher, Blaise Batumona, Pauline Afchain, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 17, 2024
Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patientsEmmanuelle Samalin, Thibault Mazard, Eric Assenat, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 7, 2013
Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohortSimon Pernot, Emmanuel Mitry, Emmanuelle Samalin, et al.
Advances in Therapy|April 14, 2022
Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE StudyDenis Smith, Côme Lepage, Eric Vicaut, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 14, 2016
Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective studyFlorence Mary, Aziz Zaanan, Valérie Boige, et al.
International Journal of Cancer|January 6, 2021
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1)Eric Assenat, Laurent Mineur, Caroline Mollevi, et al.
Oncotarget|April 29, 2015
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trialEric Assenat, David Azria, Caroline Mollevi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 7, 2019
Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failureMaïlys de Meric de Bellefon, Claire Lemanski, Florence Castan, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2017
Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effectsSimon Pernot, Cecile Badoual, Magali Terme, et al.
Targeted Oncology|April 13, 2021
The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib ProgramThomas Aparicio, Nathalie Cozic, Christelle de la Fouchardière, et al.
Pageof 7